Hindustan Laboratories IPO: Date, Price Band, GMP, Review & Should You Apply?

Hindustan Laboratories IPO 2026 — At a Glance

Hindustan Laboratories Ltd, a Mumbai-headquartered Business-to-Government (B2G) generic pharmaceuticals company, has received SEBI approval and is now in the launch queue for its mainboard IPO on BSE and NSE. The company filed its DRHP with SEBI on 3 January 2026, and SEBI issued its observation letter (effectively the green light to launch) on 27 April 2026.

The IPO has not yet opened, and the company has not yet announced the price band or the subscription dates. As soon as the Red Herring Prospectus (RHP) is filed and the dates are confirmed, our research team will publish the full details on the IPOMarket live tracker. Check Hindustan Laboratories IPO GMP live and view all upcoming IPOs 2026 for real-time updates.

This article walks you through the company, the offer structure, the financials, the strengths, the risks, and a balanced view on whether retail investors should apply once the price band is announced.

Quick Facts — Hindustan Laboratories IPO

What Does Hindustan Laboratories Do?

Hindustan Laboratories Ltd operates in a niche but extremely steady corner of the Indian pharmaceuticals industry — Business-to-Government (B2G) supply of generic medicines. Unlike traditional pharma companies that sell branded medicines through chemists and hospitals, the entire revenue base of Hindustan Laboratories comes from supplying generic medicines, in bulk, to central and state government institutions through formal procurement contracts.

To understand the model in plain terms — every state government, central government scheme, defence medical service, ESI hospital, railway hospital, public health centre, AIIMS branch, and corporation-run dispensary across India needs a continuous supply of basic generic medicines. Antibiotics, painkillers, anti-diabetics, anti-hypertensives, fever and infection medicines, and life-saving drugs need to be stocked at every district hospital, primary health centre, and urban health unit. Government procurement bodies — such as state medical service corporations, the Government Medical Stores Depot, and various state drug procurement units — float tenders inviting eligible manufacturers to bid for supply contracts.

Hindustan Laboratories is one of the established suppliers in this ecosystem. The company manufactures generic formulations at scale, qualifies for the procurement tenders, wins supply contracts, and then executes those contracts over the contract duration — typically 12 to 24 months. Because government procurement is volume-heavy and rate-contracted, margins are tighter than branded pharma, but order visibility is significantly higher and demand is non-cyclical. Public health needs do not slow down during a recession — if anything, government health spending tends to rise during downturns.

The B2G focus also means the company avoids the typical pharma headaches of branding spend, doctor relationships, retail distribution, and inventory at chemist level. The buyer is a single institutional counterparty per contract, the order is large, and the payment is from a government treasury — which is creditworthy though sometimes slow. This shapes everything about how the business runs.

Promoter Background

The promoters of Hindustan Laboratories are Rajesh Vasantray Doshi, Kunjal C. Dedhia, and Krishiv Rajesh Doshi. The three promoters collectively control the company and have built the manufacturing and procurement-bidding capability over the years.

Rajesh Vasantray Doshi is also the OFS-selling shareholder in this IPO, meaning a portion of his existing shareholding will be sold to the public as part of the offer. The other two promoters, Kunjal C. Dedhia and Krishiv Rajesh Doshi, are not selling shares in this issue. The post-IPO promoter holding will be disclosed in the Red Herring Prospectus once the price band is finalised.

For investors evaluating the company, the relevant data points to look for in the RHP will be the post-IPO promoter holding percentage, the lock-in period applicable to promoter shares (which for Indian IPOs is typically 18 months for the minimum promoter contribution and longer for the rest), and any related-party transactions disclosed in the prospectus.

IPO Structure Explained — Fresh Issue vs OFS

The Hindustan Laboratories IPO is structured as a combination of a fresh issue and an Offer for Sale (OFS). It is important for retail investors to understand the distinction because the two components have very different implications.

The fresh issue of 50 lakh shares means Hindustan Laboratories Ltd will issue brand new shares to public investors. The money raised through the fresh issue goes directly into the company's bank account and can be used for company-level purposes. According to the DRHP, the fresh issue proceeds will be used for working capital requirements and for general corporate purposes. Because the company runs a B2G procurement model — where it must manufacture and supply medicines first and then wait 60 to 120 days for government payment — working capital is a real and recurring need. Fresh equity reduces the dependence on borrowings to fund this gap.

The Offer for Sale of 91 lakh shares is different. In an OFS, no new shares are created. Instead, an existing shareholder — in this case, promoter Rajesh Vasantray Doshi — sells his existing shares to public investors. The money from the OFS goes to the selling shareholder, not to the company. The company's financials, cash position, and working capital do not change because of the OFS portion.

The total offer of 1.41 crore shares is therefore split roughly 35% fresh issue and 65% OFS. This is a meaningful detail for two reasons. First, only the fresh issue portion strengthens the company. Second, the OFS-heavy structure means a significant promoter stake is being monetised at the time of listing — a factor investors typically read in conjunction with the post-IPO promoter holding and lock-in disclosures.

Financial Performance Analysis

Hindustan Laboratories' financials show a steady, profitable B2G pharma operation. The headline numbers are below.

Reading the trajectory, three things stand out.

Revenue grew approximately 17% year-on-year between FY24 and FY25 — moving from ₹194.33 crore to ₹227.37 crore. This is solid growth for a company in the public-procurement segment, where revenue is typically a function of contracts won and executed during the year. A 17% growth indicates either a higher order book, better tender win-rate, or an expansion into new product categories or new state procurement programs.

PAT grew approximately 21% year-on-year, from ₹34.14 crore to ₹41.27 crore. Profit growth outpacing revenue growth is a healthy signal — it means the company is operating with stable to slightly improving margins. PAT margin works out to roughly 17.6% in FY24 and roughly 18.1% in FY25 — a quietly improving profitability profile.

H1 FY2026 (April to September 2025) revenue of ₹112.63 crore and PAT of ₹18.20 crore is consistent with the FY25 run-rate, though slightly back-loaded toward H2 — which is typical for B2G pharma where many state contracts have invoicing cycles concentrated in the second half of the financial year. If the second half follows the historical pattern, FY26 full-year revenue is on track to be in line with or modestly above FY25.

A note of caution on the B2G model — government procurement revenues can be lumpy. A large contract win or a delayed dispatch can move revenue meaningfully between quarters. Investors should not extrapolate from a single quarter's number; the right way to read these financials is on a trailing twelve-month and full-year basis.

Strengths

Government contract visibility. Once a generic supplier is empanelled and qualified across multiple state procurement programmes, the order pipeline tends to be steady. Procurement bodies prefer to work with proven vendors who have meet quality and delivery track records. This creates a moat that is not visible from the outside but is real in practice.

Generic pharma tailwinds in India. India is the world's largest supplier of generic medicines by volume. Domestic generic demand is structural — driven by an ageing population, rising chronic disease burden, expanding government health insurance schemes, and the steady push toward affordable medicines. Hindustan Laboratories sits in the part of the value chain that benefits the most directly from these tailwinds.

Consistent profitability. The company has been profitable in each of the disclosed years, with PAT margins above 17%. For a company at this scale, that is a respectable margin profile and indicates disciplined cost management.

Reasonable size, room to grow. At ₹227 crore of FY25 revenue, the company is small enough that a few new state contract wins or a new product approval can move the needle materially on growth.

Risks

B2G concentration risk. With essentially all revenue coming from government procurement, the company is exposed to changes in government procurement policy, tendering norms, payment delays from state treasuries, and regulatory changes around state drug procurement bodies. Diversification into private hospitals, exports, or branded generics would reduce this concentration but is not the current model.

Working capital intensity. B2G businesses typically have long receivable cycles. Government bodies pay, but they pay slowly — sometimes 90 to 180 days after invoice. This ties up cash in receivables and inventory. The fresh issue is partially intended to ease this, but working capital remains a structural need of the model.

OFS-heavy issue structure. The OFS of 91 lakh shares is meaningfully larger than the fresh issue of 50 lakh shares. While the OFS is by one of the three promoters and not all of them, retail investors typically prefer issues where a higher share of the proceeds goes to the company. The post-IPO promoter holding, lock-in details, and rationale for the OFS will need to be evaluated from the RHP.

Price band not yet known — valuation risk. The most important factor for an IPO investment decision — the issue price relative to earnings — is not yet known. A company can be a great business and still be a poor IPO investment if the price band is too aggressive. Until the price band is announced and the P/E ratio at the issue price can be compared to listed pharma peers, the application decision must remain on hold.

Regulatory and quality risks. Generic pharma manufacturing is highly regulated. Any plant inspection failure, quality deviation, or regulatory action on a manufacturing licence can disrupt revenue. Investors should read the litigation and regulatory section of the RHP carefully.

GMP (Grey Market Premium) — What to Watch

Grey Market Premium, or GMP, is an unofficial price at which IPO shares trade in the unregulated grey market between the issue close and the listing day. It is a sentiment indicator — a rough proxy for what the market expects the listing price to be. A GMP of ₹100 on a ₹500 issue, for example, suggests grey market participants expect the share to list around ₹600.

GMP for the Hindustan Laboratories IPO will be tracked on ipomarket.in once the issue opens. Until subscription opens, no meaningful GMP exists for this IPO. As soon as the price band and dates are announced, our team begins live GMP tracking from multiple sources. Check the live IPO GMP page here.

A word of caution — GMP is unofficial, unregulated, manipulated easily on illiquid issues, and is not endorsed by SEBI, NSE, or BSE. It is one signal among many. For B2G pharma issues, GMP is typically modest because these are not retail-momentum stories; they are steady businesses bought by long-term investors.

How to Apply

Once the price band and dates are confirmed, applying for the Hindustan Laboratories IPO is straightforward. Indian retail investors apply through ASBA (Application Supported by Blocked Amount) using the UPI mandate flow. The application is placed through your broker's mobile app or website — Zerodha, Upstox, Groww, Angel One, or any SEBI-registered intermediary. The application amount is blocked in your bank account via UPI mandate; if shares are allotted, the money is debited; if not, the block is released and the funds become free.

For a step-by-step walkthrough of the application process, including UPI mandate approval, lot size selection, and the cut-off price option, read our detailed guide — How to apply for an IPO online in 2026.

You can also use our IPO Allotment Calculator to estimate your chances of getting shares allotted in different oversubscription scenarios, and the IPO Subscription Status tracker to watch live demand once bidding opens.

Should You Apply?

Hindustan Laboratories is a steady, profitable B2G generic pharma company with consistent revenue and PAT growth, government procurement visibility, and a reasonable size that allows room for further expansion. The business model is defensive — public health spending is one of the most non-cyclical categories of government expenditure — and the financials reflect that defensive profile.

That said, there are two reasons why this is unlikely to be a high-momentum, high-GMP IPO. First, B2G pharma is a slow-and-steady story, not a hyper-growth narrative. Investors looking for explosive listing gains should temper expectations. Second, the issue is OFS-heavy — about 65% of the offer is a promoter exit — which limits how much of the IPO money strengthens the company.

The most important missing piece is the price band. Until the RHP is filed and the issue price is known, the valuation question — whether the P/E at the issue price is reasonable relative to listed pharma peers like Caplin Point, Eris Lifesciences, JB Chemicals, or smaller B2G peers — cannot be answered. A reasonable price band would make this an attractive subscription for moderate-risk investors looking for pharma-sector exposure with steady earnings. An aggressive price band would make the OFS structure a genuine concern.

Our preliminary view, subject to revision once the price band is announced, is that Hindustan Laboratories suits moderate-risk investors who want defensive pharma exposure and are willing to hold for the medium term. It is not a speculative listing-day-flip play. We will publish a final apply / avoid view once the RHP is out and the price band is on record. Bookmark this page and the live IPO tracker for updates.

Frequently Asked Questions

When does the Hindustan Laboratories IPO open?

The IPO open and close dates have not yet been announced. SEBI approval was received on 27 April 2026, which gives the company a 12-month window to launch. The dates will be announced when the company files the Red Herring Prospectus (RHP). Live updates are tracked on the ipomarket.in IPO calendar.

What is the price band for the Hindustan Laboratories IPO?

The price band has not been announced yet. It will be confirmed in the RHP, typically a few days before the subscription opens. As soon as it is announced, ipomarket.in will publish the price band and the lot size on the live tracker.

What is the issue size of the Hindustan Laboratories IPO?

The total issue size is 1.41 crore equity shares of face value ₹10 each — comprising a fresh issue of 50 lakh shares and an Offer for Sale of 91 lakh shares by promoter Rajesh Vasantray Doshi. The total rupee value will depend on the final price band.

Who is the lead manager and registrar for this IPO?

Choice Capital Advisors Pvt. Ltd. is the sole Book Running Lead Manager (BRLM). MUFG Intime India Pvt. Ltd. is the registrar to the issue. The registrar handles the application processing and the allotment.

Is the IPO available for SME or mainboard listing?

This is a mainboard IPO, listing on both BSE and NSE. It is not an SME issue. The minimum application size will follow the standard mainboard SEBI guidelines (one lot in the ₹13,000–₹15,000 range for retail).

What does Hindustan Laboratories actually do?

Hindustan Laboratories manufactures and supplies generic medicines in bulk to central and state government institutions through procurement contracts. It is a Business-to-Government (B2G) model — the entire customer base is government health bodies, public hospitals, and state-run procurement programmes.

How healthy are the company's financials?

Revenue grew from ₹194.33 crore in FY24 to ₹227.37 crore in FY25, a growth of approximately 17%. PAT grew from ₹34.14 crore to ₹41.27 crore, approximately 21% growth, reflecting stable to slightly improving margins. H1 FY26 revenue was ₹112.63 crore with PAT of ₹18.20 crore.

Where can I track the GMP and live subscription status for this IPO?

Once the issue opens, real-time GMP is published at /gmp and live subscription multiples (QIB, NII, retail, and total) are published at /subscription. Both pages refresh frequently during the bidding window. You can also use the IPO Allotment Calculator to estimate your allotment probability after the issue closes.

Disclaimer: This article is published by IPOMarket Research Team for educational and informational purposes only. It does not constitute investment advice, a recommendation to buy or sell any security, or an offer to invest. IPO investments are subject to market risks. Please read all scheme-related documents carefully and consult a SEBI-registered financial advisor before investing. ipomarket.in is not a SEBI-registered investment advisor or research analyst.